Cerenome (CNSY) vs Cytosorbents (CTSO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Cytosorbents (CTSO) has outperformed Cerenome (CNSY) over the past year, losing 80.9% versus a loss of 90.5%. Over five years, CTSO leads with a -96.8% price change compared with -99.7% for CNSY. Cerenome is the larger company by market cap ($13.6 million vs $11.8 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CNSY | CTSO |
|---|---|---|
| Share price | $1.79 | $3.73 |
| Market cap | $13.59M | $11.75M |
| 1-day change | +9.48% | -3.62% |
| YTD return | -85.96% | -70.81% |
| 1-year return | -90.45% | -80.87% |
| 5-year return | -99.73% | -96.82% |
| EPS (TTM) | $-3.36 | $-5.80 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $19.00 | $19.72 |
| 52-week low | $1.49 | $3.66 |
| Distance from 52-week high | -90.58% | -81.09% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +1450.28% | +1173.46% |
| Average volume | 121.12K | 12.45K |
| Shares outstanding | 7.59M | 3.15M |
| Employees | 28 | 129 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Medical Devices |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Cerenome
CNSY stock →Cerenome, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.
Healthcare · Biotechnology · 28 employees
About Cytosorbents
CTSO stock →Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform in the United States, Germany, and internationally. Its flagship product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses, bilirubin in liver failure, myoglobin in trauma and critical illnesses, and inflammatory mediators and blood thinners in cardiac surgery applications, as well as to remove antithrombotic drugs and inflammatory mediators in cardiothoracic surgery applications.
Healthcare · Medical Devices · 129 employees
CNSY vs CTSO FAQ
Which is bigger, Cerenome or Cytosorbents?
Cerenome (CNSY) is larger, with a market capitalization of $13.59M compared with $11.75M for Cytosorbents (CTSO).
Which stock has performed better over the past year, CNSY or CTSO?
CTSO returned -80.87% over the past 12 months, compared with -90.45% for CNSY (price return, excluding dividends). Past performance does not predict future results.
Are Cerenome and Cytosorbents in the same industry?
Both are in the Healthcare sector, but in different industries: Biotechnology for Cerenome and Medical Devices for Cytosorbents.